Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Vir Biotechnology, Inc. (VIR)

NewAmsterdam Pharma Company N.V. and Vir Biotechnology, Inc. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Vir Biotechnology, Inc. are of similar size ($2.3B and $2.3B). Vir Biotechnology, Inc. grew revenue faster over the last twelve months: 1,696.0% against −26.4%. Vir Biotechnology, Inc. has the higher net margin (−61.0% vs −789.9%) and the higher return on invested capital (−30.3% vs −13,975.8%). Across the 16 metrics below, Vir Biotechnology, Inc. leads on 11 and NewAmsterdam Pharma Company N.V. on 5.

Valuation

Metric NAMS VIR Biotechnology median
P/E n/m n/m 11.58
P/S 98.69 7.33 9.61
P/B 4.06 2.48 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 74.41 5.81 9.43
Earnings yield (8.20%) (9.52%) (32.28%)
Free cash flow yield (5.89%) (6.39%) (22.27%)

Profitability

Metric NAMS VIR Biotechnology median
Gross margin 100.00% 99.99% 68.81%
Operating margin (900.07%) (69.82%) 0.00%
Net margin (789.94%) (61.03%) 0.00%
Free cash flow margin (581.64%) (46.87%) 0.00%
Return on equity (30.16%) (21.84%) (50.30%)
Return on assets (27.79%) (17.34%) (45.47%)
Return on invested capital (13,975.75%) (30.32%) 0.00%

Growth

Metric NAMS VIR Biotechnology median
Revenue growth (TTM) (26.41%) 1,695.96% 6.78%
EPS growth (last fiscal year) 32.81% 17.49% 29.88%
Revenue growth, 5-year CAGR — (2.14%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS VIR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.76 6.30 4.74
Net debt to EBITDA 2.83 1.02 1.01

Dividend

Metric NAMS VIR Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric NAMS VIR Biotechnology median
Market cap 2.30b 2.25b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack